Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ENOVNASDAQ:LMATNASDAQ:NVCROTCMKTS:WEDXF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENOVEnovis$31.86-1.3%$33.24$29.13▼$49.83$1.82B1.71832,899 shs1.37 million shsLMATLeMaitre Vascular$81.13-0.3%$83.86$71.42▼$109.58$1.83B0.83169,218 shs229,261 shsNVCRNovoCure$17.55-3.6%$17.46$14.17▼$34.13$1.96B0.741.18 million shs1.35 million shsWEDXFWestaim$23.73+1.0%$22.70$16.62▼$25.98$506.81M0.247,317 shs13,300 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENOVEnovis0.00%+0.22%-11.75%-18.78%-28.95%LMATLeMaitre Vascular0.00%-3.57%-4.29%-4.68%+1.30%NVCRNovoCure0.00%+3.24%-1.90%-10.41%-17.76%WEDXFWestaim0.00%+2.75%+3.15%+11.86%+693.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENOVEnovis2.9968 of 5 stars3.42.00.00.02.51.71.9LMATLeMaitre Vascular2.9127 of 5 stars2.22.03.30.03.02.51.3NVCRNovoCure3.9396 of 5 stars3.34.00.04.51.61.70.0WEDXFWestaim0.6593 of 5 stars0.03.00.00.01.90.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENOVEnovis 2.80Moderate Buy$58.0082.05% UpsideLMATLeMaitre Vascular 2.33Hold$97.8320.59% UpsideNVCRNovoCure 2.67Moderate Buy$32.8387.08% UpsideWEDXFWestaim 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest WEDXF, LMAT, NVCR, and ENOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.005/9/2025ENOVEnovisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.005/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $57.004/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.004/16/2025NVCRNovoCureWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $27.004/10/2025NVCRNovoCureJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $28.004/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.004/2/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENOVEnovis$2.15B0.85$4.64 per share6.86$62.66 per share0.51LMATLeMaitre Vascular$226.26M8.10$1.44 per share56.52$13.38 per share6.06NVCRNovoCure$621.71M3.15N/AN/A$3.39 per share5.18WEDXFWestaim$8.63M58.73$9.02 per share2.63$23.72 per share1.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENOVEnovis-$33.26M-$13.95N/A9.99N/A-5.95%4.39%2.80%8/6/2025 (Estimated)LMATLeMaitre Vascular$30.10M$1.9844.3337.392.2219.40%13.15%11.47%7/30/2025 (Estimated)NVCRNovoCure-$207.04M-$1.51N/AN/AN/A-25.93%-41.48%-12.74%7/24/2025 (Estimated)WEDXFWestaim$183.98M-$2.1713.64∞N/A284.74%7.76%7.29%8/12/2025 (Estimated)Latest WEDXF, LMAT, NVCR, and ENOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025WEDXFWestaim-$0.0316-$0.34-$0.3084-$0.34$1.34 million($4.70) million5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/1/2025Q1 2025LMATLeMaitre Vascular$0.50$0.48-$0.02$0.48$57.61 million$59.87 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million3/26/2025Q4 2024WEDXFWestaim$0.0618-$0.99-$1.0518-$0.99$4.70 million$4.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENOVEnovisN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.99%N/A40.40%14 YearsNVCRNovoCureN/AN/AN/AN/AN/AWEDXFWestaim$0.090.38%N/AN/A N/ALatest WEDXF, LMAT, NVCR, and ENOV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2025LMATLeMaitre Vascularquarterly$0.201%5/15/20255/15/20255/29/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENOVEnovis0.402.271.12LMATLeMaitre VascularN/A7.745.52NVCRNovoCure0.271.491.44WEDXFWestaimN/A11.8111.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENOVEnovis98.45%LMATLeMaitre Vascular84.64%NVCRNovoCure84.61%WEDXFWestaimN/AInsider OwnershipCompanyInsider OwnershipENOVEnovis2.70%LMATLeMaitre Vascular9.50%NVCRNovoCure5.52%WEDXFWestaim4.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENOVEnovis6,80057.12 million55.49 millionOptionableLMATLeMaitre Vascular49022.59 million20.06 millionOptionableNVCRNovoCure1,320111.49 million101.40 millionOptionableWEDXFWestaim721.36 million20.46 millionNot OptionableWEDXF, LMAT, NVCR, and ENOV HeadlinesRecent News About These CompaniesThe Westaim Co. (OTCMKTS:WEDXF) Short Interest UpdateJune 15 at 1:20 AM | marketbeat.comWestaim (OTCMKTS:WEDXF) Shares Down 0.3% - What's Next?June 1, 2025 | marketbeat.comThe Westaim Corporation Reports Q1 2025 ResultsMay 14, 2025 | businesswire.comCC Capital and Westaim Complete Transaction, Creating Integrated Insurance and Asset Management PlatformApril 3, 2025 | businesswire.comWestaim Announces Receipt of Required Regulatory Approvals in Connection with CC Capital TransactionMarch 27, 2025 | businesswire.comThe Westaim Corporation Announces Normal Course Issuer BidMarch 26, 2025 | businesswire.comThe Westaim Corporation Reports Q4 and Full Year 2024 Results and Update on Timing of Proposed Transactions with CC CapitalMarch 26, 2025 | businesswire.comWestaim completes acquisition of ManhattanLifeFebruary 6, 2025 | insurancebusinessmag.comWestaim: Transforming Into A Potential Long-Term Compounding MachineJanuary 30, 2025 | seekingalpha.comThe Westaim Corp WEDXDJanuary 15, 2025 | morningstar.comThe Westaim Corporation Announces Completion of ArrangementJanuary 2, 2025 | businesswire.comWestaim: Stocks Undervalued by Analyst Consensus on TSX-V (WED)December 22, 2024 | theglobeandmail.comThe Westaim Corporation appoints CRODecember 6, 2024 | complianceweek.comThe Westaim Corporation Files Management Information Circular for Special Shareholders Meeting and Encourages Shareholders to Access Meeting Materials OnlineNovember 27, 2024 | newsfilecorp.comThe Westaim Corporation Files Management Information Circular for Special Shareholders Meeting and Encourages Shareholders to Access Meeting Materials OnlineNovember 27, 2024 | newsfilecorp.comCC Capital & Westaim partner on new integrated insurance and asset management platformOctober 11, 2024 | reinsurancene.wsCC Capital and Westaim to create insurance and asset management platformOctober 9, 2024 | pehub.comWestaim Corporation: A Bargain In The Asset Management WorldSeptember 4, 2024 | seekingalpha.comWestaim Corporation: Still Undervalued Based On NAVJuly 19, 2024 | seekingalpha.comThe Westaim Corporation (WEDXF)May 19, 2024 | finance.yahoo.comWestaim: Q1 Earnings SnapshotMay 14, 2024 | timesunion.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWEDXF, LMAT, NVCR, and ENOV Company DescriptionsEnovis NYSE:ENOV$31.86 -0.43 (-1.33%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$31.91 +0.05 (+0.16%) As of 06/13/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.LeMaitre Vascular NASDAQ:LMAT$81.13 -0.24 (-0.29%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$80.47 -0.66 (-0.82%) As of 06/13/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.NovoCure NASDAQ:NVCR$17.55 -0.65 (-3.57%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$17.43 -0.12 (-0.68%) As of 04:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Westaim OTCMKTS:WEDXF$23.73 +0.22 (+0.95%) As of 06/13/2025 03:59 PM EasternThe Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
